| Changes to trial information |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Primary Outcome, Time from first dose to sustained clinical resolution, day-28 |
Primary Outcome, Time from first dose to sustained clinical resolution, day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, 28-day all-cause mortality , day-28 |
Secondary Outcome, 28-day all-cause mortality , day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, Time to first negative blood qRT-PCR , day-28 |
Secondary Outcome, Time to first negative blood qRT-PCR , day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, change in viral load from baseline, day-3, day-5, day-7 |
Secondary Outcome, change in viral load from baseline, day-3, day-5, day-7 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, Time to resolution of individual signs and symptoms, day-3, day-5, day-7, day-13, day-21, day-28 |
Secondary Outcome, Time to resolution of individual signs and symptoms, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, progression to critical stage, day-3, day-5, day-7, day-13, day-21, day-28 |
Secondary Outcome, progression to critical stage, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, need for advanced care, day-3, day-5, day-7, day-13, day-21, day-28 |
Secondary Outcome, need for advanced care, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, In-hospital all-cause mortality prior to discharge, Discharge |
Secondary Outcome, In-hospital all-cause mortality prior to discharge, Discharge in post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, time from randomisation to hospital discharge, Discharge |
Secondary Outcome, time from randomisation to hospital discharge, Discharge in post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Primary Outcome, Incidence and severity of adverse events and serious adverse events , day-3, day-5, day-7, day-13, day-21, day-28 |
Primary Outcome, Incidence and severity of adverse events and serious adverse events , day-3, day-5, day-7, day-13, day-21, day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Primary Outcome, Events leading to treatment discontinuation, day-3, day-5, day-7, day-13, day-21, day-28 |
Primary Outcome, Events leading to treatment discontinuation, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Primary Outcome, clinically significant laboratory abnormalities, day-3, day-5, day-7, day-13, day-21, day-28 |
Primary Outcome, clinically significant laboratory abnormalities, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Primary Outcome, events of special interest (hypersensitivity; hepatic, renal and cardiac signals)., day-3, day-5, day-7, day-13, day-21, day-28, day-56 |
Primary Outcome, events of special interest (hypersensitivity; hepatic, renal and cardiac signals)., day-3, day-5, day-7, day-13, day-21, day-28, day-56 post-intervention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Outcome |
OutCome List |
24/08/2026 |
Clarification when the outcome will be assessed |
Secondary Outcome, Health status, day-56 |
Secondary Outcome, Health status, day-56 post-intevention |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Reporting |
IPD description |
24/08/2026 |
Updated in response to the ClinicalTrials.gov review comment to include the required IPD sharing statement and clarify that de-identified participant-level data may be shared with qualified researchers under controlled-access conditions.
|
No |
De-identified individual participant data underlying the reported results of the ORACLE-BDBV trial will be made available to qualified researchers following approval of a scientifically sound request. Direct identifiers and variables that present an unacceptable risk of participant re-identification will not be shared. Data sharing will be consistent with the informed consent document, applicable ethical, legal, and regulatory requirements, and relevant institutional and sponsor policies. |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Reporting |
IPD-Sharing time frame |
24/08/2026 |
Updated in response to the reviewer comments for time frame of IPD-sharing
|
Not applicable |
After the analysis and the publication of the data |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Reporting |
Key access criteria |
24/08/2026 |
Updated in response to the reviewer comments for key access criteria. |
Not applicable |
Will be defined later by investigator and the sponsor. |